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A small library of chalcones induce 
liver cancer cell death through Akt 
phosphorylation inhibition
irem Durmaz Sahin 1*, Michael S. christodoulou2, ece Akhan Guzelcan3, Altay Koyas 3, 
cigdem Karaca4, Daniele passarella 5 & Rengul cetin‑Atalay 3
Hepatocellular carcinoma (HCC) ranks as the fifth most common and the second deadliest cancer 
worldwide. Hcc is extremely resistant to the conventional chemotherapeutics. Hence, it is vital to 
develop new treatment options. chalcones were previously shown to have anticancer activities in 
other cancer types. In this study, 11 chalcones along with quercetin, papaverin, catechin, Sorafenib 
and 5FU were analyzed for their bioactivities on 6 HCC cell lines and on dental pulp stem cells (DPSC) 
which differentiates into hepatocytes, and is used as a model for untransformed control cells. 3 of the 
chalcones (1, 9 and 11) were selected for further investigation due to their high cytotoxicity against 
liver cancer cells and compared to the other clinically established compounds. chalcones did not show 
significant bioactivity ( IC
50
> 20µM ) on dental pulp stem cells. cell cycle analysis revealed that these 
3 chalcone-molecules induced SubG1/G1 arrest. Akt protein phosphorylation was inhibited by these 
molecules in PTEN deficient, drug resistant, mesenchymal like Mahlavu cells leading to the activation 
of p21 and the inhibition of NFκB-p65 transcription factor. Hence the chalcones induced apoptotic 
cell death pathway through nfκB-p65 inhibition. On the other hand, these molecules triggered p21 
dependent activation of Rb protein and thereby inhibition of cell cycle and cell growth in liver cancer 
cells. Involvement of PI3K/Akt pathway hyperactivation was previously described in survival of 
liver cancer cells as carcinogenic event. therefore, our results indicated that these chalcones can be 
considered as candidates for liver cancer therapeutics particularly when PI3K/Akt pathway involved in 
tumor development.
Hepatocellular carcinoma (HCC) ranks as the fifth most common and the second deadliest cancer type 
 worldwide1. The prognosis of HCC requires a multi-step process starting with chronic liver disease progressing 
through formation of dysplastic nodules and resulting in liver carcinogenesis upon gathering of different genomic 
 alterations2. HCC is extremely resistant to conventional chemo- and radio-therapies3. The FDA (US-Food and 
Drug Administration) agency approved targeted drug for advanced HCC is Sorafenib which can only prolong 
survival 2–5  months4. Thus it is crucial to develop new treatment or prevention strategies for HCC. Sorafenib, 
which is a multikinase inhibitor acts trough RAF/MEK/ERK pathway and VEGFR/PDGFR tyrosine kinases. 
Therefore, alternative signaling pathways involved in liver cancer cell survival can be targeted in liver cancer 
 therapy5. PI3K/Akt pathway was shown to be hyperactive in liver cancer cells which can be exploited for this 
 purpose6. PI3K/Akt pathway is critical in the regulation of cell proliferation, cell survival and  angiogenesis7–9. 
The lipid phosphatase and tensin homolog (PTEN) negatively regulates the activation of Akt by PI3K. The loss 
of PTEN tumor suppressor leads to the constitutive activation of Akt by PI3K, hence leading to the activation of 
cell survival and growth. PTEN deletion is frequently observed in  HCC10. Therefore this pathway plays a central 
role in the development of several cancers including  HCC8, 11, 12. The deletion of PTEN, activation mutation of 
PI3K or other receptor tyrosine kinases may result in deregulation of PI3K/Akt pathway in HCC. Especially 
PTEN was previously shown to be deleted in Mahlavu cells, which is mesenchymal-like drug resistant poor dif-
ferentiated aggressive HCC cell  line13.
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Chalcones are a group of natural compounds that are widely found in the plant  kingdom14. Their structure 
is presented in a variety of biologically active molecules including synthetic and natural products and are con-
sidered as open chain intermediates in the synthesis of  flavones15. Chalcones possess a wide range of biological 
properties such as anti-viral, anti-oxidant, anti-fungal, anti-inflammatory, anti-microbial, anti-HIV and anti-
cancer  activities16, 17. The presence of the α,β-unsaturated carbonyl motif is believed to be responsible for their 
biological activities since chalcones act as Michael acceptors by trapping thiols in a biological  media18. Different 
pathways have been elucidated in which chalcones induce their activity. Therefore, chalcones can be used as 
inhibitors of the multi-drug resistance (MDR) Channels, the hormonal Milieu, histone deacetylases (HDAC), 
the p53 degradation, the JAK/STAT signaling pathway, angiogenesis, and cellular proliferation. Furthermore, 
chalcones are exploited as cytotoxic  agents19.
In this study, following our interest in the synthesis and the identification of compounds with anticancer 
related  bioactivities20–32, eleven chalcones were synthesized and tested against HCC cell lines and dental pulp stem 
cells which are reported to be hepatic progenitor  properties33. DPSCs can proliferate and differentiate rapidly into 
various lineages including hepatocytes therefore they present a good model for untransformed control  cells34. 
We documented that three of the molecules were highly cytotoxic toward poorly differentiated aggressive liver 
cancer cells. Treatment with these molecules resulted in SubG1/G1 cell cycle arrest induced apoptosis through 
deregulation of Akt related pathways.
Results
chemistry. General procedure for the preparation of chalcones. An aqueous solution of sodium hydroxide 
(30%, 25 mL) was slowly added to a methanol solution (30 mL) of the appropriate acetophenone (5.0 mmol). 
After the solution had been cooled to room temperature, the appropriate benzaldehyde (6.0 mmol) was added. 
The mixture was stirred at room temperature overnight and was then poured into water (100 mL). The obtained 
solid was filtered, washed with water until neutral pH and recrystallized from ethanol. The synthesized chal-
cones are presented in Fig. 1.
pharmacology. Cytotoxic evaluation of the synthesized compounds. The bioactivities of the synthesized 
chalcones were assessed on human liver cancer cell lines and on DPSCs with NCI-SRB assay in vitro. DPSCs 
used to asses the bioactivity of chalcones on untransformed control cells with the potential of hepatic  lineage34. 
The cells were treated with the range of increasing concentrations of the compounds (2.5–40 μM) for 72 h. We 
also included 5-Fluorouracil which is used in clinics for gastrointestinal cancers and Sorafenib. All results were 
normalized to DMSO negative control measurements. The experiment was performed in triplicate. Results re-
vealed that especially compounds 1, 2, 5, 6, 9 and 11 possess high bioactivities in liver cancer cells (Table 1). 
Compounds 1, 9 and 11 were chosen for further analysis due to their higher bioactivities on aggressive, poorly-
differentiated liver cancer cell lines (Mahlavu, FOCUS, SNU475) compared to the other chalcones tested in this 
study (Table 1).
Figure 1.  Structures of the synthesized chalcones.
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The selected 3 compounds were further analyzed with real-time cell electronic sensing (RT-CES) system to 
assess the real-time growth behavior of the cells treated with the compounds. Huh7 and Mahlavu liver cancer cells 
were treated with the selected chalcones and monitored with RT-CES. Results of the compounds were normalized 
to data of negative control DMSO. RT-CES experiment suggested that the compounds were more effective in the 
first 12–24 h of the treatment, then the bioactivities of the compounds stayed stable (Fig. 2).
Characterization of the cell death induced by chalcones. Human liver cancer cells Mahlavu and Huh7 were 
treated with the compounds according to the  IC50 values obtained from RT-CES experiments or DMSO controls 
for 72hr. Hoechst-dye-stained cells were observed under fluorescent microscope revealing distinctive morphol-
ogies comparing to DMSO controls. Nuclear condensation and horse-shoe like structures suggests apoptosis 
induction which need to be further confirmed with detailed experiments (Fig. 3A). We further assessed the 
effects of the selected chalcones 1, 9, and 11 on the cell cycle progression analysis of liver cancer cells. Human 
liver cancer cells Mahlavu and Huh7 were treated with the compounds according to the  IC50 values obtained 
from RT-CES for 72 h. Then the DNA in the treated cells were stained with propidium iodide and analyzed with 
fluorescent-activated cell sorter. Results showed that the chalcones induced SubG1 cell cycle arrest in human 
liver cancer cell lines (Fig. 3B). The type of cell death induced by the compounds was suggested to be apoptosis 
with the results of Hoechst nuclear staining and cell cycle analysis. In order to confirm the induction of apopto-
sis in human liver cancer cells treated with the chalcones, cleavage of PARP protein (marker of apoptosis) was 
investigated. Western blot results indicated that PARP cleavage was present significantly in cells treated with 9 
and 11 (Fig. 3C). These results confirmed that the compounds induced apoptotic cell death in liver cancer cells.
Cellular pathway components targeted by the chalcones 1, 9, 11. In order to investigate the significant bioactivity 
of the chalcones 1, 9 and 11 on human liver cancer cell line Mahlavu which has an hyperactive PI3K/Akt path-
way due to PTEN-deficiency13, we analyzed the effect of the chalcones on the active phosphorylated Akt levels in 
this cell line. Western blot analysis revealed that treatment with all three compounds resulted in decrease in the 
levels of pAkt upon treatment for 24 h with  IC50 values given in Fig. 2 (Fig. 4A,B). The decrease in the Akt protein 
phosphorylation suggested that the chalcones interfere with Akt protein activation in Mahlavu cells (Fig. 4A,B) 
which is more pronounced in the treatments with 9 and 11.
In the literature, it was shown that the anti-cancer effect of chalcones on uterus leiomyoma cells was through 
an increase in p21  protein35. Thus we also examined the levels of p21 in our cells. Furthermore, p21 is also a 
downstream element of Akt pathway. The results presented in Fig. 4A,C indicated that, the p21 protein levels 
were increased significantly in cells treated with chalcones 9 and 11, 9, being the most significant (Fig. 4). Cell 
cycle analysis revealed a cell cycle arrest induced by the compounds (Fig. 3B). Therefore, the effect on Rb pro-
tein, which is also a downstream element of p21, was investigated in the presence of the chalcones 1, 9 and 11. 
The phosphorylated Rb protein levels were decreased significantly in the cells treated with 9 and 11 (Fig. 4). 
This suggested that, treatment with the compounds resulted in activation of Rb through its dephosphorylation 
(Fig. 4A,C) inducing cell cycle arrest (Fig. 3B).
NFB is a transcription factor which is a fundamental component of inflammation pathway. This protein has 
also crucial roles in cell proliferation and apoptosis, thus cancer  progression36. In addition, previous studies 
showed that cardamonin analogs (type of chalcones) suppress NFB pathway in lung cancer  cells37. Since the 
inflammation is one of the hallmarks of cancer, we also investigated the effect of our compounds on NFB protein. 
The phosphorylation of NFB-p65 at Ser468 decreased significantly upon treatment with 9 and 11 (Fig. 4A,D). 
Table 1.  IC50 ( µM ) values of the compounds. DPSC dental pulp stem cells, NI no Inhibition  (IC50 > 40 (μM)), 
NA not applicable, R2 > 0.8.
Huh7 HepG2 Hep3B Mahlavu FOCUS SNU475 DPSC
1 1.3 4.2 6.2 2.2 4.9 3 NI
2 4.1 5.8 5.6 5.1 11.4 9.8 28.7
3 6.4 7.6 18 9.4 20 13.1 NI
4 44.4 51.6 NI* 24.8 NI 23.8 NI
5 3 9.1 8.5 9.2 5.4 14.5 NI
6 6.4 7.6 7.8 6.3 6.5 10 NI
7 44.9 58.9 47.5 31.1 NI NI NI
8 17.9 26 22.1 17.3 21.5 21.6 NI
9 5.3 7.3 7.3 6.3 3.3 5 25.7
10 11.9 13.9 16.5 14.6 15.9 20 NI
11 4.3 6.5 5.9 5.3 3.1 9 19.1
Quercetin 12.5 8.4 21.8 11.3 17.9 11.6 21.2
Papaverine hydrochloride 8.5 4.9 20.4 52.3 1.7 17.8 NI
Catechin hydrate NI NI NI NI NI NI NI
Sorafenib 1.3 5.6 NA 7.9 NA 7.5 7.1
5-Fluorouracil 30.7 5 15.2 10 7.7 NA 23.7
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This form of NFB is the activated form which translocates into the nucleus to function as a transcription factor. 
Decrease in this phosphorylated form of the protein suggested that NFB-p65 is altered upon treatment with the 
chalcones 9 and 11 (Fig. 4A,D).
Figure 2.  Real-time cell growth analysis. Human liver cancer cells Huh7 (left panel) and Mahlavu (right 
panel) were treated with the selected compounds. Cell index measurements were obtained by RT-CES software. 
DMSO was used as negative control. (A) The growth inhibition values of the compounds were obtained by the 
normalization with DMSO. Experiments were performed in triplicate. (B)  IC50 values calculated from RT-CES 
experiment data.
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Discussion
In this study, recently synthesized chalcones were the first time examined for their anti-proliferative properties 
in cancer cells and compared with 5-FU and Sorafenib. 5-FU is a chemotherapeutic agent frequently used in 
gastrointestinal cancers and Sorafenib is the first FDA (US-Food and Drug Administration) agency approved 
drug in primary liver cancer. Most of the compounds had moderate to significant bioactivities on liver cancer 
cells tested (Table 1). Furthermore drugs had no significant cytotoxic activity on dental pulp stem cells which 
we used a model for untransformed hepatic progenitor cells. 3 of the compounds (1, 9 and 11) were selected for 
further analysis according to their bioactivities on poorly differentiated aggressive liver cancer cells (Table 1 and 
Fig. 2). The cell death analysis with the chalcones 1, 9 and 11 revealed that these three molecules induce SubG1 
cell cycle arrest and apoptosis (Fig. 3). Previously it was shown that several different pathways can be targeted 
with chalcones in various cancers. In this study, PTEN-deficient, Akt hyperactive aggressive liver cancer cell 
line Mahlavu cells were treated with the newly synthesized chalcones and molecular mechanism of action were 
analyzed. Treatment with the compounds induced decrease in pAkt levels suggesting induction of an inhibition 
of Akt protein (Fig. 3). Moreover, decrease in phosphorylated NFB-p65 (Ser468) and increase in p21 protein 
were observed in treated cells (Fig. 4). Akt protein was previously shown be one of the regulators of the activi-
ties of these two  proteins38, 39. Thus, alteration of Akt protein activity by the chalchones result in the activation 
of p21 protein along with the inhibition of NFB-p65 protein phosphorylation. NFB-p65 is a transcription factor 
Figure 3.  Cell death induced by the chalcones. (A) Nuclear staining of the liver cancer cells treated with the 
chalcones. Human liver cancer cells (Huh7 and Mahlavu) were treated with the  IC50 concentrations of the 
chalcones 1, 9, 11. After 72 h of incubation with the compounds or DMSO control, Hoechst (33258) staining 
was performed. Images were taken with fluorescent microscope (×40). Due to the strong cytotoxic activities 
of the chalcones the number of the cells in objective area was much less than DMSO controls. (B) Cell cycle 
distribution of liver cancer cells. Huh7 and Mahlavu cells were treated for 72 h with  IC50 concentrations of the 
compounds or DMSO control. SubG1 cell cycle arrest was observed upon treatment with the compounds (blue). 
(C) Investigation of PARP cleavage in Huh7 and Mahlavu cells treated with the selected chalcones for 24 h.
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which is activated by phosphorylation and then translocate into  nucleus36, 40. Our compounds causes decrease 
in its phosphorylation and thereby its activity. Active NFB-p65 was shown to have fundamental role in cancer 
progression by inhibition of  apoptosis36, 41. Thus, the alteration in phosphorilation of NFB-p65 by the chalcones 
9 and 11 results in induction of apoptosis in liver cancer cells (Fig. 4). Moreover, in the cells treated with the 
compounds, phosphorylation of Rb protein, which is a cell cycle regulator, was decreased. Under normal condi-
tions, during cell division Rb protein is inhibited by phosphorylation. Decrease in the phosphorylation of Rb, 
meaning its activation, results in cell cycle arrest in human liver cancer cells treated with the chalchones 1, 9 and 
11 (Fig. 4). In this study our results indicates that these newly synthesized chalcones can be considered as good 
candidates for liver cancer therapeutics particularly chalcone 9. For future perspectives, the design of new class 
of compounds with this scaffold will be studied with the aim to improve the in vitro performance and analyze 
the activity of the compounds in vivo on animal models.
Methods
cell culture. Well differentiated human primary liver cancer cell lines Huh7, HepG2 and Hep3B, and poorly 
differentiated Mahlavu, FOCUS and SNU475 HCC cells were cultured in Dulbecco’s Modified Eagle’s Standard 
(DMEM) medium supplemented with 10% Fetal Bovine Serum (FBS), 100 units/mL penicillin and 100 lg/mL 
streptomycin (Gibco, Invitrogen, Carlsbad, CA, USA). 0.1 mM nonessential amino acids (NEAA) which are 
specific to HCC cell lines also added to culture media. Cells were cultured in a 5% CO2 incubator at 37 ◦C
Dental pulp stem cell isolation. Dental pulp stem cells (DPSCs) were isolated from anonymised uni-
dentified healthy intact wisdom tooth. DPSCs were isolated within few hours upon wisdom teeth surgery from 
patients above 18 years old. All were informed about the procedures, and their consents were obtained. Teeth 
were broken carefully in order to reach the dental pulp area. After the surgical extraction, pulp tissues from 
Figure 4.  Proteins targeted by the compounds. Human liver cancer cells (Mahlavu) were treated with the  IC50 
concentrations of the selected compounds or DMSO control for 24 h. (A) Western blot analysis showed that 
Akt protein is inhibited in liver cancer cells treated with the compounds resulting in alterations of p21 and 
NFkB proteins. (B–D) Quantification of the results using ImageJ software. (E) Schematic representation of the 
molecular mechanism of action of the compounds. Blocked signaling is crossed.
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maxillary and mandibular teeth were washed several times with ice-cold PBS (Gibco, Cat: 14190-169) and 
transferred within 2 hours on ice into DMEM-F12 media (Gibco, Cat: 11320033) supplemented with 10% FBS 
(Gibco, Cat: 10270), 1× Penicillin & Streptomycin (Gibco, Cat:15140-122), 2,5 µg/ml Amphotericin B (Biologi-
cal Industries, Cat:03-028-1B) and 5 µg/ml Plasmocin (Invivogen, Cat: ant-mpp). Pulp tissue was shredded by 
scalpel and chemically digested with Liberase (Merck, Cat: 5401089001) approx. 1 U/ml for 45 minutes at 37 ◦C . 
Then, the cells were seeded onto flasks in 10ml DMEM-F12 media (Lonza) supplemented with 1% penicillin/
streptomycin solution (Hyclone) and 15% FBS (Fetal Bovine Serum,Hyclone, Logan, UT, USA) and cultured in 
a 5% CO2 incubator at 37 ◦C . 10 day of culturing was usually optimal to obtain DPSCs.
Dental pulp stem cell characterizaton with flow cytometry. Trypsinized (Biological Industries, 
Cat: BI03-052-1B) cells were collected and washed with ice-cold PBS once. Next, cells were fixed with 4% Para-
formaldehyde (Sigma, Cat:158127) in PBS for 20 minutes at room temperature and centrifuged at 1500 rpm for 
5 minutes; following by resuspension in stain buffer (BD, Cat: 554656) in a concentration scale of 1 × 106 cells/
ml. Following antibodies were used as described; EpCAM-APC (BD, 347200) (1:100 v/v), CD133-PE (BioLe-
gend, 372804) (1:100 v/v), CD44-FITC (Miltenyi Biotec, Cat: 130-095-195) (1:10 v/v) and CD90-FITC (Milte-
nyi Biotec, Cat: 130-095-403) (1:10 v/v). For unstained controls, IgG1 Isotypes; IgG1-FITC (Immunostep, Cat: 
ICIGG1F-100), IgG1-PE (Immunostep, Cat: ICIGG1PE-50), and IgG1-APC (BD, Cat: 555751); were used as 
1:20 (v/v). For staining, cells were incubated with antibodies for 30 minutes in room temperature at dark and 
washed once with staining buffer. Stained cells were analyzed on NovoCyte Flow Cytometer System (Acea) and 
analysis was performed via NovoExpress Software (Supplementary Fig. S1).
NCI-60 sulforhodamine B assay for in vitro cytotoxicity screening. Primary liver cancer cells 
Huh7, HepG2, Hep3B, Mahlavu, FOCUS, Snu475 along with hepatic progenitor Dental pulp stem cells were 
seeded into 96-well plates (1,000–3,000 HCC cell/well and 10,000 cells DPSC/well ) for 24 h. The cells were then 
treated with increasing concentrations of the chalcones ( 2.5− 40µM ). DMSO (AppliChem Biochemica, Darm-
stadt, Germany) was used as negative control. The growth has stopped at the end of 72 h by fixing cold with 10% 
(v/v) trichloroacetic acid (Merck, Schuchardt, Germany). Cells were then stained with 0.4% (m/v) of sulforho-
damine (Sigma-Aldrich, St. Louis, USA) in 1% acetic acid solution. The absorbency values were acquired at 515 
nm. All experiments were done in triplicate.
Real‑time cell electronic sensing (Rt‑ceS analysis). Huh7 and Mahlavu cells were inoculated into 
the e-plate (1000–2000 cells/well). The attachment, spreading, and proliferation of the cells were monitored 
every 30 minutes using the  Xcelligence® Real-Time Cell Analysis system (ACEA Biosciences Inc.) in a cell culture 
incubator. The electronic readout (cell-sensor impedance) was displayed as an arbitrary unit called the cell index 
(CI). When cells reach to an cell index (CI) impedance values about 1.5 usually in 24 hours cells were treated 
with the chalcones 1, 9 and 11. DMSO was used as a negative control. Each experiment was repeated three times. 
The CI value was noted every 10 minutes for the first 24 hours and then every 30 minutes upon chalcone treat-
ments. The cell inhibition rate calculated as follows (%) = [1− (CItreatedcells/CIDMSO)] × 100.
nuclear stain. Huh7 and Mahlavu cells were inoculated in 6-well plates for 24 h. The cells were treated with 
 IC50 concentrations (Table 1) of the compounds (1, 9 and 11) for 72 h. Hoescht 33258 (Sigma–Aldrich) staining 
was done to visualize the nuclear condensation. Cells were fixed with 1 mL of cold methanol and the samples 
were incubated with 3 mg/mL of Hoescht, and examined under fluorescent microscopy (40×).
cell cycle analysis. Cells were treated with  IC50 concentrations of the chalcones (1, 9 and 11)(Table 1) for 
72 h. Then samples were stained with propidium iodide which binds to DNA and analyzed with  MUSE® Cell 
Cycle Assay Kit (EMD Milipore).
Western blot analysis. Poorly differentiated liver cancer cell line Mahlavu cells were cultured in 100 mm 
culture dish for 24 h. Growth medium was then replaced with  IC50 concentrations of chalcones 1, 9 and 11 or 
DMSO (control) supplemented medium. cells were incubated for 24 hours then were scraped and collected for 
western blot analysis. Anti-PARP antibody (Cell Signaling, 9532), pAkt (Ser473) antibody (Cell Signaling, 9271), 
Akt antibody (Cell Signaling, 9272), pNFkB-p65 (Ser468) antibody (Snat Cruz, sc101750), p21 antibody (Milli-
pore, 05345), pRb (Ser807/811) antibody (Cell Signaling, 9308), Rb antibody (Santa Cruz, sc102), actin antibody 
(Sigma, A5441) and calnexin antibody (Sigma, C4731) were used as primary antibodies. Anti-rabbit (6154) and 
anti-mouse (0168) secondary antibodies were used. ImageJ tool (42) used for protein band intensity comparison. 
Original Full length blots are given as Supplementary Information.
ethics statement. The study and use of dental pulp cells was approved by Hacettepe University (permit no 
2019/06-49) and informed consent was obtained from all participants. (All patients were above 18 years old). 
The study was conducted according to the institutional guidelines and regulations.
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